MINI FUTURE OPTIONSSCHEIN PUT - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 03:34:36 2024-06-28 pm EDT | ||
| 3.57 EUR | +2.00% |
|
| Current month | -10.08% | ||
| 1 month | -10.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 3.57 | +2.00% |
| 24-06-27 | 3.5 | +0.86% |
| 24-06-26 | 3.47 | +1.46% |
| 24-06-25 | 3.42 | +4.59% |
| 24-06-24 | 3.27 | -2.39% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:34 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | DZ BANK |
| WKN | DW67FQ |
| ISIN | DE000DW67FQ7 |
| Date issued | 2022-11-03 |
| Strike | 106.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.15 € |
|---|---|
| Lowest since issue | 1.72 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.61
USD
Average target price
82.97
USD
Spread / Average Target
+20.93%
- Stock Market
- Certificates
- Certificat
